Agepha Pharma News Today

Payal Kohli, MD, discusses how recent advancements have changed conversations surrounding modifiable cardiovascular risk and what it means for practitioners.

Check out this week’s medical marketing news, people on the move and industry chatter.

Several new drugs have appeared on the scene, and a long-familiar anti-inflammatory splashed into the cardiology space.

Major regulatory news and RCTs topped the list, but COVID-19 and the opioid pandemic had an impact, as did a UK TAVI furor.

While promising, the technology has much to prove, including how much it really adds to standard risk prediction.

Drug pricing should be subject to stricter regulation

COP-AF trial results showed no significant reduction in co-primary endpoints of clinically important AF or myocardial injury after noncardiac thoracic surgery, although there were positive trends.

Aspirin is typically given after PCI for acute coronary syndrome but can lead to major bleeding. Colchicine appears to be safer and may be equally efficacious, pilot data suggest.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

Americans pip Dutch to the post in heart medicine registration